Site-Centric Digital Transformation: Redesigning Clinical Trial Technology Around Investigator Needs

The clinical trial ecosystem has a structural imbalance that is becoming increasingly unsustainable. For decades, clinical trial technology has been designed, procured, and deployed from the sponsor’s perspective, optimizing for the data collection, oversight, and regulatory submission needs of pharmaceutical companies and contract research organizations. Investigator sites, the organizations and individuals who actually conduct clinical research, interact with patients, and generate the data upon which regulatory decisions are made, have been treated as end users of sponsor-selected technology rather than as primary stakeholders whose needs should drive technology design.

The consequences of this sponsor-centric approach are now manifesting as a workforce crisis at research sites. Clinical research coordinators, the professionals who form the operational backbone of clinical trial execution, are leaving the field at alarming rates, citing technology burden, administrative overload, and burnout as primary drivers. Investigator sites report spending half or more of their coordinator time on administrative and technology tasks rather than on the patient-facing research activities that attracted them to clinical research and that ultimately determine trial quality. The technology that was supposed to make clinical research more efficient has instead created a sprawling, fragmented administrative environment that is driving away the very people the industry depends on to conduct trials.

This article examines the technology burden facing investigator sites, the emerging site-centric approaches that are beginning to address it, and the strategic implications for sponsors, CROs, and technology vendors who must recognize that site sustainability is not an externality to be managed but a prerequisite for clinical trial success.

The Site Burden Crisis in Clinical Trials

To appreciate the urgency of site-centric technology transformation, it is necessary to understand the scale and nature of the burden that current technology approaches impose on investigator sites.

The System Proliferation Problem

A typical academic medical center or dedicated research site conducting trials for multiple sponsors simultaneously may be required to operate anywhere from seven to twelve or more distinct technology systems at any given time. Each sponsor brings its own electronic data capture system, interactive response technology platform, clinical trial management system, eTMF, and various ancillary systems for safety reporting, electronic consent, patient-reported outcomes, and wearable device management. Each of these systems has its own user interface, login credentials, training requirements, and operational workflows. The result is a technology environment that resembles nothing so much as an air traffic controller’s screen, except that the air traffic controller at least benefits from an integrated display.

The proliferation problem is compounded by the fact that these systems are not static. Sponsors regularly update their technology platforms, sometimes mid-study, requiring sites to learn new interfaces and adapt established workflows. New studies bring new system configurations even within familiar platforms, as each sponsor’s implementation of a given technology may differ significantly in data entry requirements, workflow rules, and user interface customization.

The Dual-Entry Burden

Perhaps the most costly manifestation of the sponsor-centric technology model is the requirement for dual data entry. In the traditional clinical trial workflow, clinical data is first captured in the site’s electronic health record system as part of routine clinical care, and then transcribed into the sponsor’s electronic data capture system as part of the trial data collection process. This transcription step requires coordinators to locate the relevant data in the EHR, navigate to the corresponding field in the EDC system, enter the data, and then verify that the transcribed data matches the source record. For a complex study protocol with hundreds of data points per visit, this transcription process can take hours per patient per visit, consuming coordinator time that could be spent on direct patient interaction or other higher-value activities.

The dual-entry problem also introduces a systematic data quality risk. Every manual transcription step is an opportunity for error, and studies have consistently shown that transcription errors account for a significant proportion of data queries generated during clinical trials. These queries, in turn, generate additional work for site coordinators who must research the discrepancy, correct the data if necessary, and document the resolution, creating a self-reinforcing cycle of administrative burden.

The Sponsor-Centric Design Problem

The root cause of the site burden crisis is a fundamental misalignment between who designs clinical trial technology and who uses it. Understanding this misalignment is essential for designing solutions that address the problem rather than perpetuating it.

Technology Procurement Dynamics

Clinical trial technology purchasing decisions are made by sponsors and CROs, not by investigator sites. This means that the economic buyer of clinical trial technology is not the primary user of clinical trial technology, and the buyer’s requirements, which emphasize data standardization, regulatory compliance, oversight capabilities, and cost efficiency, do not necessarily align with the user’s requirements, which emphasize workflow efficiency, minimal training burden, interoperability with existing clinical systems, and minimal disruption to patient care activities.

This purchasing dynamic creates a market incentive structure that prioritizes sponsor needs over site needs. Technology vendors optimize their products for the buyers who select them, which means optimizing for sponsor-facing features such as data oversight dashboards, compliance reporting, and regulatory submission capabilities rather than for site-facing features such as intuitive data entry interfaces, EHR integration, and cross-sponsor workflow standardization. Sites, who bear the consequences of these design priorities but have no vote in the selection process, are left to adapt to whatever systems their sponsors choose.

The One-Size-Fits-All Protocol Problem

Sponsor-centric technology design manifests not only in system selection but in protocol design and technology configuration. Protocols are designed by sponsor medical teams with limited understanding of site operational constraints, and the technology configurations that implement those protocols often demand data collection schedules, source documentation practices, and workflow requirements that are impractical within the realities of a busy clinical research operation. When site coordinators raise concerns about operational feasibility, the typical response is to provide additional training on the sponsor’s system rather than to reconsider whether the system or protocol demands are reasonable.

The Technology Reality at Investigator Sites

Designing effective site-centric technology requires understanding the actual technology environment in which investigator sites operate, which varies dramatically across different types of research organizations.

Academic Medical Centers

Academic medical centers typically have sophisticated health IT infrastructure including enterprise EHR systems, research data warehouses, and institutional CTMS platforms. However, this infrastructure is designed for the institution’s clinical care and academic research missions, and clinical trial technology from sponsors must coexist with and often work around this existing infrastructure. EHR integration is theoretically feasible at academic centers but practically challenging due to institutional IT governance requirements, EHR vendor cooperation timelines, and the cost of building and validating integrations for each sponsor’s systems.

Dedicated Research Sites and Networks

Dedicated research sites and site networks that conduct clinical trials as their primary business have different technology characteristics. These organizations may have invested in their own site-level CTMS and operational technology, and the most sophisticated site networks have built technology platforms that standardize operations across their network of locations. However, even the most technology-forward site networks face the same fundamental challenge: they must still operate whatever systems each sponsor brings to the table, and they have limited ability to influence those systems.

Community Practices and New-to-Research Sites

Community physician practices and healthcare organizations that are new to clinical research face the most acute technology challenges. These sites may have minimal research IT infrastructure, limited technical support staff, and no established processes for managing multiple research technology systems. The technology burden of participating in clinical trials can be overwhelming for these sites, and the difficulty of technology adoption is a significant barrier to expanding clinical trial participation into community settings where diverse patient populations can be reached.

eSource and Direct Data Capture: The Foundation of Site-Centric Design

Electronic source data capture, commonly referred to as eSource, represents the most fundamental shift toward site-centric clinical trial technology. Rather than requiring sites to transcribe data from their clinical systems into sponsor EDC systems, eSource approaches capture clinical trial data directly from the systems and workflows that sites already use for patient care.

EHR-to-EDC Data Flow

The most impactful eSource approach involves establishing automated data flows from the site’s EHR system to the sponsor’s EDC system, eliminating the manual transcription step for data that is captured in the EHR as part of routine clinical care. This approach requires interoperability standards that enable structured data exchange between EHR and EDC systems, mapping specifications that define how EHR data elements correspond to EDC form fields, and quality controls that verify data accuracy and completeness during the automated transfer process.

The FHIR (Fast Healthcare Interoperability Resources) standard has emerged as the primary technical foundation for EHR-to-EDC data exchange, and both EHR vendors and clinical trial technology vendors have made significant investments in FHIR-based interoperability. Major EHR platforms now offer FHIR APIs that enable external systems to query and retrieve patient data, and several EDC vendors have developed FHIR-based connectors that can consume this data and populate EDC forms automatically.

Point-of-Care Data Capture

An alternative eSource approach embeds clinical trial data capture directly into the site’s clinical workflow, presenting trial-specific data collection forms within the EHR or point-of-care system rather than requiring the coordinator to switch to a separate EDC application. This approach minimizes workflow disruption by keeping the research data collection within the same system environment that the site uses for all patient interactions. Several technology vendors have developed EHR-integrated research modules that enable this point-of-care capture approach, and early adopters report significant reductions in data entry time and error rates.

Site Clinical Trial Management Systems

While sponsor-provided CTMS platforms manage trials from the sponsor’s perspective, a parallel category of site-level CTMS has emerged to manage trials from the site’s perspective. These systems address the fundamental operational need for sites to manage their entire research portfolio, across all sponsors and studies, through a single integrated platform.

Core Site CTMS Capabilities

• Portfolio-level study management: Tracking all active studies, regardless of sponsor, through a unified dashboard that provides visibility into enrollment status, visit schedules, protocol deviations, and operational metrics across the site’s entire research portfolio.
• Patient visit scheduling and tracking: Managing patient visit schedules across all active studies, identifying scheduling conflicts, and coordinating the complex logistics of patients who may be enrolled in multiple studies simultaneously.
• Regulatory document management: Maintaining site-level regulatory files including investigator CVs, laboratory certifications, IRB correspondence, and delegation logs in a centralized repository that serves all studies.
• Financial management: Tracking study budgets, invoicing milestones, and payment status across all sponsor relationships, providing the financial visibility that sites need to manage research as a sustainable business operation.
• Staff management: Managing training records, delegation assignments, and credential expiration tracking for research staff across all active studies.

Veeva’s recent announcement of a research site CTMS represents a significant development in this space, as it brings the resources and platform integration capabilities of a major clinical technology vendor to the site-level CTMS market. The entry of established platform vendors into the site CTMS space signals recognition that site operational efficiency is a critical enabler of sponsor trial success and that the market for site-centric technology is large enough to justify significant investment.

The Unified Site Portal Vision

The most ambitious articulation of the site-centric technology vision is the unified site portal: a single interface through which site staff can access all sponsor systems, manage all study-related tasks, and maintain visibility into their complete research operation without needing to navigate multiple disconnected applications.

Architecture of a Unified Portal

A unified site portal sits as an integration layer between site staff and the multiple sponsor systems they must interact with, providing a consistent user experience while routing data and actions to the appropriate underlying systems. The portal aggregates tasks, notifications, and data entry requirements from all active studies into a single prioritized work queue, enabling coordinators to manage their workload efficiently without logging into each sponsor system individually. The portal also provides cross-study visibility into patient schedules, protocol requirements, and regulatory deadlines that no individual sponsor system can offer because each sponsor system only knows about its own study.

The technical challenges of building a unified site portal are significant. The portal must integrate with the diverse technology systems that different sponsors use, each with different APIs, data models, and authentication mechanisms. It must maintain regulatory compliance, ensuring that data entered through the portal meets the same audit trail, electronic signature, and data integrity requirements as data entered directly into each sponsor’s system. And it must evolve as sponsor systems are updated, new studies are initiated, and new technology platforms are introduced into the site’s portfolio.

Industry Initiatives

Several industry initiatives are working toward the unified portal vision, with varying approaches and levels of maturity. The TransCelerate BioPharma Shared Investigator Platform initiative has brought together major pharmaceutical companies to develop a common platform for site-facing interactions, focusing initially on site qualification and regulatory document exchange. The Clinical Trials Transformation Initiative has published recommendations for reducing site burden through technology standardization, and several technology vendors are developing portal solutions that aggregate site workflows across multiple sponsor systems.

Interoperability: Connecting Sponsor and Site Systems

The technical foundation for site-centric clinical trial technology is interoperability: the ability of different systems to exchange data and coordinate workflows seamlessly and without manual intervention. Without robust interoperability standards and implementations, site-centric technology remains an aspiration rather than a reality.

Standards Landscape

EHR Integration and Clinical Workflow Alignment

The most impactful form of site-centric technology transformation is deep integration between clinical trial technology and the electronic health record systems that form the operational center of modern healthcare delivery. EHR integration goes beyond eSource data extraction to encompass a comprehensive alignment between research and clinical workflows.

Bidirectional Data Flow

True EHR integration is bidirectional. Data flows from the EHR to clinical trial systems, eliminating transcription, and relevant trial information flows back to the EHR, ensuring that the patient’s clinical record reflects their participation in research. This bidirectional flow enables clinicians to see research participation status, study medications, and protocol-driven procedures within the same clinical record they use for care delivery, improving safety by ensuring that all caregivers are aware of the patient’s research involvement and any protocol-specific requirements that may affect clinical decisions.

Research Identification and Screening

EHR integration also enables automated identification of patients who may be eligible for clinical trials based on their clinical data. EHR-based screening algorithms can continuously evaluate the patient population against active trial eligibility criteria, alerting research staff when potentially eligible patients are identified. This capability transforms patient recruitment from a manual chart review process into an automated, continuous identification process that operates across the institution’s entire patient population.

Financial Sustainability and Site Economics

The technology burden on sites is not only an operational issue but an economic one. Investigator sites must sustain their research operations as economically viable enterprises, and the technology costs, both direct and indirect, of participating in clinical trials significantly affect site financial sustainability.

Direct Technology Costs

While sponsors typically provide access to their technology systems at no direct cost to sites, the indirect costs of operating these systems are substantial. Sites must maintain IT infrastructure capable of running multiple web-based applications simultaneously, provide technical support for staff encountering system issues, and absorb the productivity costs of staff time spent on technology-related activities rather than billable research tasks. These indirect technology costs are rarely fully compensated in study budgets, creating a structural underfunding of the technology infrastructure that clinical trials depend on.

The Coordinator Retention Economics

The economic impact of technology burden on coordinator retention is perhaps the most significant financial consideration for sites. Recruiting and training a new clinical research coordinator represents an investment of tens of thousands of dollars, and the lost productivity during the learning curve for a new coordinator affects study timelines and data quality across the site’s entire portfolio. When technology burden is a primary driver of coordinator turnover, the cost of that turnover is attributable, at least in part, to the technology environment that drove the departure.

Reducing the Training and Credential Burden

Training requirements for clinical trial technology represent a significant and growing component of site burden. Each sponsor system requires initial training, often including system-specific certifications, and ongoing training as systems are updated or new features are deployed.

The Training Multiplication Effect

A site running ten concurrent studies for different sponsors may face training requirements for ten different EDC systems, ten different IRT platforms, and various ancillary systems for each study. Even when different sponsors use the same underlying technology platform, each sponsor’s configuration may differ sufficiently to require sponsor-specific training. The result is that research staff spend a material portion of their time in training activities that are largely redundant, learning the same fundamental concepts, data entry practices, and safety reporting procedures through different sponsor-specific training programs.

Credential Management Complexity

Beyond training, the management of system credentials across multiple sponsor platforms creates its own administrative burden. Research staff must maintain unique credentials for each system, manage password changes across multiple platforms, and ensure that their system access remains current as study assignments change. Password fatigue and credential management complexity are not trivial concerns; they are daily operational friction points that consume time and generate frustration.

Single sign-on solutions and federated identity management approaches can significantly reduce the credential burden, but adoption of these technologies in clinical trial systems remains limited. Sponsors and technology vendors have been slow to implement federated identity standards that would allow site staff to use institutional credentials to access sponsor systems, despite the clear operational benefits and the maturity of the underlying technology.

Measuring and Improving the Site Experience

Improving the site experience requires measurement, and the industry is developing metrics and assessment frameworks that enable systematic evaluation of technology burden and site satisfaction.

Site Satisfaction Metrics

Forward-thinking sponsors are beginning to incorporate site satisfaction metrics into their technology evaluation and selection processes. These metrics include system usability scores measured through standardized instruments, time-and-motion studies that quantify the time required for specific technology tasks, site satisfaction surveys that assess overall technology experience across sponsors, and technology-related query and support request rates that indicate system usability issues. By systematically measuring site experience, sponsors can identify the technology decisions that create the greatest burden and prioritize improvements that have the most significant impact on site operations.

The Path Forward: Building a Site-Centric Ecosystem

The transition from sponsor-centric to site-centric clinical trial technology will not happen through any single technology deployment or vendor selection. It requires a sustained, multi-stakeholder effort that addresses technology standards, economic models, organizational culture, and industry governance.

Immediate Actions for Sponsors

• Conduct site technology burden assessments for your current trial portfolio, quantifying the number of systems, training hours, and administrative time that your technology decisions impose on sites.
• Prioritize eSource adoption for data elements that are routinely captured in site EHR systems, eliminating dual data entry for the highest-volume data points.
• Standardize technology platforms across your study portfolio where possible, reducing the number of distinct systems that sites must learn and operate for your trials.
• Include site experience criteria in technology vendor evaluation and selection processes, weighting site usability alongside sponsor-facing capabilities.
• Compensate sites fairly for the technology costs they absorb, including IT infrastructure, technical support, and the productivity impact of technology complexity.

Medium-Term Industry Initiatives

Beyond individual sponsor actions, the industry as a whole must invest in the standards, platforms, and governance structures that enable site-centric technology at scale. Interoperability standards must mature to the point where data can flow seamlessly between site and sponsor systems without custom integration for each sponsor-site pair. Shared infrastructure for common site-facing functions, including regulatory document exchange, training management, and credential management, must be developed and adopted broadly enough to meaningfully reduce site burden. And the economic model for clinical trial technology must evolve to recognize sites as stakeholders whose needs deserve investment, not just end users whose adaptation is assumed.

The Long-Term Vision

The long-term vision for site-centric clinical trial technology is an ecosystem where research is embedded seamlessly into clinical care delivery, where technology enables rather than burdens the professionals who conduct clinical research, and where the data needed for regulatory decision-making flows from clinical workflows without requiring a parallel administrative infrastructure dedicated solely to clinical trial data collection. Achieving this vision requires sustained commitment from all stakeholders: sponsors who invest in site-centric technology even when it requires adapting their own processes, technology vendors who design for site users rather than only for sponsor buyers, regulators who create frameworks that accommodate integrated clinical-research workflows, and sites that articulate their technology needs and hold their sponsor partners accountable for addressing them.

The site burden crisis is not a problem that can be solved with incremental improvements to the current technology model. It requires a fundamental rethinking of how clinical trial technology is designed, deployed, and operated, placing the investigator and the coordinator at the center of the design process rather than at the end of the deployment pipeline. Organizations that lead this transformation will not only address the immediate workforce crisis but will build the operational foundation for a more efficient, more sustainable, and ultimately more successful clinical trial enterprise.